80 patients with LN (37 of them accepted immunosuppressive therapy and followed up for 6 months) and 20 HC who underwent blood samples to analyze the roles of IL-17 and IL-23 in monitoring activity and predicting response to treatment in LN. This evidence concerns the gene IL17A and lobular neoplasia.